AIMS: To quantify blood Delta(9)-tetrahydrocannabinol (THC) concentrations in chronic cannabis users over 7 days of continuous monitored abstinence. PARTICIPANTS: Twenty-five frequent, long-term cannabis users resided on a secure clinical research unit at the US National Institute on Drug Abuse under continuous medical surveillance to prevent cannabis self-administration. MEASUREMENTS: Whole blood cannabinoid concentrations were determined by two-dimensional gas chromatography-mass spectrometry. FINDINGS: Nine chronic users (36%) had no measurable THC during 7 days of cannabis abstinence; 16 had at least one positive THC > or =0.25 ng/ml, but not necessarily on the first day. On day 7, 6 full days after entering the unit, six participants still displayed detectable THC concentrations [mean +/- standard deviation (SD), 0.3 +/- 0.7 ng/ml] and all 25 had measurable carboxy-metabolite (6.2 +/- 8.8 ng/ml). The highest observed THC concentrations on admission (day 1) and day 7 were 7.0 and 3.0 ng/ml, respectively. Interestingly, five participants, all female, had THC-positive whole blood specimens over all 7 days. Body mass index did not correlate with time until the last THC-positive specimen (n = 16; r = -0.2; P = 0.445). CONCLUSIONS: Substantial whole blood THC concentrations persist multiple days after drug discontinuation in heavy chronic cannabis users. It is currently unknown whether neurocognitive impairment occurs with low blood THC concentrations, and whether return to normal performance, as documented previously following extended cannabis abstinence, is accompanied by the removal of residual THC in brain. These findings also may impact on the implementation of per se limits in driving under the influence of drugs legislation.
AIMS: To quantify blood Delta(9)-tetrahydrocannabinol (THC) concentrations in chronic cannabis users over 7 days of continuous monitored abstinence. PARTICIPANTS: Twenty-five frequent, long-term cannabis users resided on a secure clinical research unit at the US National Institute on Drug Abuse under continuous medical surveillance to prevent cannabis self-administration. MEASUREMENTS: Whole blood cannabinoid concentrations were determined by two-dimensional gas chromatography-mass spectrometry. FINDINGS: Nine chronic users (36%) had no measurable THC during 7 days of cannabis abstinence; 16 had at least one positive THC > or =0.25 ng/ml, but not necessarily on the first day. On day 7, 6 full days after entering the unit, six participants still displayed detectable THC concentrations [mean +/- standard deviation (SD), 0.3 +/- 0.7 ng/ml] and all 25 had measurable carboxy-metabolite (6.2 +/- 8.8 ng/ml). The highest observed THC concentrations on admission (day 1) and day 7 were 7.0 and 3.0 ng/ml, respectively. Interestingly, five participants, all female, had THC-positive whole blood specimens over all 7 days. Body mass index did not correlate with time until the last THC-positive specimen (n = 16; r = -0.2; P = 0.445). CONCLUSIONS: Substantial whole blood THC concentrations persist multiple days after drug discontinuation in heavy chronic cannabis users. It is currently unknown whether neurocognitive impairment occurs with low blood THC concentrations, and whether return to normal performance, as documented previously following extended cannabis abstinence, is accompanied by the removal of residual THC in brain. These findings also may impact on the implementation of per se limits in driving under the influence of drugs legislation.
Authors: Eugene W Schwilke; Erin L Karschner; Ross H Lowe; Ann M Gordon; Jean Lud Cadet; Ronald I Herning; Marilyn A Huestis Journal: Clin Chem Date: 2009-03-05 Impact factor: 8.327
Authors: Franjo Grotenhermen; Gero Leson; Günter Berghaus; Olaf H Drummer; Hans-Peter Krüger; Marie Longo; Herbert Moskowitz; Bud Perrine; Johannes G Ramaekers; Alison Smiley; Rob Tunbridge Journal: Addiction Date: 2007-10-04 Impact factor: 6.526
Authors: Ross H Lowe; Erin L Karschner; Eugene W Schwilke; Allan J Barnes; Marilyn A Huestis Journal: J Chromatogr A Date: 2007-07-06 Impact factor: 4.759
Authors: Robert S Goodwin; William D Darwin; C Nora Chiang; Ming Shih; Shou-Hua Li; Marilyn A Huestis Journal: J Anal Toxicol Date: 2008-10 Impact factor: 3.367
Authors: Garry Milman; Allan J Barnes; David M Schwope; Eugene W Schwilke; Robert S Goodwin; Deana L Kelly; David A Gorelick; Marilyn A Huestis Journal: Anal Bioanal Chem Date: 2011-06-03 Impact factor: 4.142
Authors: Mark Asbridge; Robert Mann; Michael D Cusimano; Cynthia Trayling; Michael Roerecke; John M Tallon; Alyce Whipp; Jürgen Rehm Journal: Int J Public Health Date: 2013-09-24 Impact factor: 3.380
Authors: Nicolas J Schlienz; Edward J Cone; Evan S Herrmann; Natalie A Lembeck; John M Mitchell; George E Bigelow; Ronald Flegel; Charles P LoDico; Eugene D Hayes; Ryan Vandrey Journal: J Anal Toxicol Date: 2018-05-01 Impact factor: 3.367
Authors: Mallory J E Loflin; Brian D Kiluk; Marilyn A Huestis; Will M Aklin; Alan J Budney; Kathleen M Carroll; Deepak Cyril D'Souza; Robert H Dworkin; Kevin M Gray; Deborah S Hasin; Dustin C Lee; Bernard Le Foll; Frances R Levin; Joshua A Lile; Barbara J Mason; Aimee L McRae-Clark; Ivan Montoya; Erica N Peters; Tatiana Ramey; Dennis C Turk; Ryan Vandrey; Roger D Weiss; Eric C Strain Journal: Drug Alcohol Depend Date: 2020-04-26 Impact factor: 4.492
Authors: Sarah K Himes; Karl B Scheidweiler; Olof Beck; David A Gorelick; Nathalie A Desrosiers; Marilyn A Huestis Journal: Clin Chem Date: 2013-09-17 Impact factor: 8.327
Authors: Eugene W Schwilke; David M Schwope; Erin L Karschner; Ross H Lowe; William D Darwin; Deanna L Kelly; Robert S Goodwin; David A Gorelick; Marilyn A Huestis Journal: Clin Chem Date: 2009-10-15 Impact factor: 8.327
Authors: Mateus M Bergamaschi; Erin L Karschner; Robert S Goodwin; Karl B Scheidweiler; Jussi Hirvonen; Regina H C Queiroz; Marilyn A Huestis Journal: Clin Chem Date: 2013-03 Impact factor: 8.327